As the first tumor-specific inhibitor of miRNAs, MRX34 has entered phase 1 clinical trials in patients with hepatocellular carcinoma and other solid tumors to correct the normal expression of miRNAs or overexpression in tumor cells [28]. The gene discussed is IL1RAPL1; the disease is hepatocellular carcinoma.